 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Assistant Clinical Professor of Pharmacy Practice, Auburn University Harrison School of Pharmacy, University of South Alabama, Mobile, AL
Associate Clinical Professor of Pharmacy Practice, Auburn University Harrison School of Pharmacy, University of Alabama at Birmingham, Huntsville Regional Medical Campus
Reprints: Dr. Karwa, Auburn University Harrison School of Pharmacy, University of South Alabama, Health Services Building, Ste. 2100, Mobile, AL 36688, fax 251/445-9341, rzk0004{at}auburn.edu
OBJECTIVE: To review the use of efungumab as an adjunctive agent in the treatment of invasive candidiasis (IC) and to provide guidance on formulary placement.
DATA SOURCES: Searches of MEDLINE (1966–June 2009) and EMBASE (1974–June 2009) were conducted using the terms efungumab, Mycograb, heat shock protein 90, and invasive candidiasis. Other resources included www.clinicaltrials.gov and article bibliographies.
STUDY SELECTION AND DATA EXTRACTION: All studies and case reports evaluating efungumab use in IC were included. Literature review was limited to the English language.
DATA SYNTHESIS: Efungumab is a monoclonal antibody targeted against heat shock protein 90 (HSP 90). It binds to HSP 90, preventing a conformational change needed for fungal viability. In vitro data show that HSP 90 inhibition may decrease resistance against antifungal agents and increase antifungal activity. Efungumab shows activity against Candida spp. when used alone and synergism when combined with fluconazole, caspofungin, and amphotericin B. A randomized controlled trial evaluated combination therapy of efungumab 1 mg/kg twice daily and liposomal amphotericin B versus amphotericin B therapy alone. At day 10, a favorable response was seen in 84% of patients in the efungumab group compared with 48% of patients in the placebo group (OR 5.76; 95% CI 2.4 to 13.8). Mortality at day 33 was also lower in the efungumab group, 4% versus 18%, respectively (OR 0.168; 95% CI 0.036 to 0.797). Although adverse effects were similar in this trial (10% vs 7%), case reports revealed an increased incidence of blood pressure fluctuations. Cytokine release syndrome has also been linked to efungumab use, warranting further exploration of its safety.
CONCLUSIONS: Efungumab is a new antifungal agent with a novel mechanism of action. Available clinical data and synergy studies support the use of efungumab in combination with other antifungal agents for the treatment of IC. Further safety data are needed before formulary recommendations can be made.
Key Words: efungumab, heat shock protein 90, invasive candidiasis, Mycograb
Published Online, September 22, 2009. www.theannals.com, DOI 10.1345/aph.1M218
 |
 |
 |
 |
 |
 |
 |
